Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens

Antimicrob Agents Chemother. 2014 May;58(5):2964-7. doi: 10.1128/AAC.00053-14. Epub 2014 Feb 24.

Abstract

Adequate penetration to the infection/colonization site is crucial to attain optimal efficacy of posaconazole against Aspergillus fumigatus diseases. We evaluated posaconazole exposure in pulmonary epithelial lining fluid (ELF) in a murine model of invasive pulmonary aspergillosis. The posaconazole exposure (area under the plasma concentration-time curve from time zero to 24 h postinfusion [AUC0-24]) in ELF was 20% to 31% of that in plasma for total drug after the third dose, and the relationship between plasma and ELF exposure was linear (r(2) = 0.97, P = 0.016).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / therapeutic use*
  • Disease Models, Animal
  • Female
  • Invasive Pulmonary Aspergillosis / blood
  • Invasive Pulmonary Aspergillosis / drug therapy*
  • Invasive Pulmonary Aspergillosis / metabolism
  • Mice
  • Triazoles / administration & dosage
  • Triazoles / pharmacokinetics
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Triazoles
  • posaconazole